Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 5/20 | 0.58 |
| ▸ | MMP13 | P45452 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331127 | 0.78 | MMP12 (0.57) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL6340411 | 0.78 | MMP12 (0.59) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL6413671 | 0.77 | MMP12 (0.69) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL6412998 | 0.77 | MMP12 (0.56) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL6413015 | 0.77 | MMP12 (0.56) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL27542526 | 0.76 | MMP12 (0.78) | MMP12MMP13 | |
| SCHEMBL6350414 | 0.76 | MMP12 (0.78) | MMP12MMP13 | |
| SCHEMBL6419152 | 0.75 | MMP12 (0.66) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL7790155 | 0.75 | MEN1 (0.51) | MMP12MMP13HTTLMNAMAPT | |
| SCHEMBL6339753 | 0.75 | MMP12 (0.79) | MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885HTT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.